Semuloparin is an investigational selectively engineered Ultra-LMWH (low molecular weight heparin) with enriched anti-thrombin binding sites. Semuloparin reduced the risk of this type of blood clots without increasing
The results from the trial suggested that at five years 66% of patients taking Glivec for three years remained free of cancer recurrence (primary endpoint) compared to 48%
Developed by Genentech and Novartis, Lucentis is an antibody fragment that is injected into the eye and acts by neutralizing VEGF. The EC’s approval was given on the
In addition to being an investigational pan-BCR-ABL inhibitor for use in chronic myeloid leukemia (CML), ponatinib inhibits certain other tyrosine kinases, including a specific mutation of FLT3 called
The double-blind, placebo-controlled study is designed to measure the efficacy, safety and tolerability of STX209, an oral selective gamma-amino butyric acid type B (GABA-B) receptor agonist. GABA-B receptors
Under the agreement, Biowa will receive the right to certain antibody technology from IMUC and selected option rights to IMUC antibodies using the POTELLIGENT Technology. POTELLIGENT Technology involves
PAT-LM1 is a natural human antibody that has been shown to have anti-cancer properties, in multiple animal models, including a potent effect in models of pancreatic, lung and
The capsules are the generic version of Wyeth’s Effexor XR capsules, which are used in the treatment of major depressive disorder and social anxiety disorder. Mylan is launching
Pfizer and Zhejiang Hisun Pharmaceuticals will explore a potential business collaboration focused on manufacturing cooperation to deliver and commercialize medicines through a local and global sales and marketing
Confab is a Montreal-based pharmaceutical manufacturing company with licenses from both FDA and European regulatory bodies, as well as certain Asian countries to manufacture drugs for human use.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.